Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data
Sign Up to like & getrecommendations! Published in 2017 at "Diabetes Therapy"
DOI: 10.1007/s13300-017-0225-z
Abstract: IntroductionIn this literature review we evaluated the real-world clinical effectiveness of switching Japanese diabetic patients from their current insulin regimen to insulin degludec (IDeg).MethodsStudies were identified from Japanese Diabetes Society (JDS) abstracts (2014–2015) and PubMed… read more here.
Keywords: insulin; real world; change; weighted mean ... See more keywords
Insulin degludec allows for better glycaemic control with a lower risk of hypoglycaemia in patients with chronic kidney disease and type 2 diabetes.
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes Research and Clinical Practice"
DOI: 10.1016/j.diabres.2020.108094
Abstract: Abstract We conducted a retrospective observational study to demonstrate that switching to insulin degludec from other long-acting insulins reduces the risk of hypoglycaemia events and improves glycaemic control in patients with type 2 diabetes and… read more here.
Keywords: chronic kidney; glycaemic control; type diabetes; risk hypoglycaemia ... See more keywords
A comprehensive stability assessment of insulin degludec using New customized validated RP-HPLC and SEC-HPLC methods in an orthogonal testing protocol.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of pharmaceutical and biomedical analysis"
DOI: 10.1016/j.jpba.2021.114175
Abstract: Stress testing of biopharmaceuticals plays an important role in preparation of their stability profiles through investigation of possible degradation pathways and identification of degradation products, so in this study Insulin Degludec which is a new… read more here.
Keywords: degradation; hplc; sec hplc; insulin degludec ... See more keywords
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Sign Up to like & getrecommendations! Published in 2021 at "The Lancet"
DOI: 10.1016/s0140-6736(21)01443-4
Abstract: BACKGROUND Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist under development for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of tirzepatide versus titrated insulin… read more here.
Keywords: degludec; tirzepatide versus; hba1c; insulin degludec ... See more keywords
Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2018.1389888
Abstract: ABSTRACT Introduction: Co-formulation of basal and bolus insulin components provides a simpler regimen for patients with type 2 diabetes than separate basal–bolus treatment. However, conventional premixed insulin products include a suboptimal protaminated basal component that… read more here.
Keywords: degludec insulin; insulin; basal; japanese patients ... See more keywords
Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2017.1313109
Abstract: ABSTRACT Introduction: A fixed combination of basal insulin degludec and glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide (IDegLira; 50 units degludec/1.8 mg liraglutide) has been developed as a once daily injection for the treatment of type… read more here.
Keywords: insulin; combination; liraglutide insulin; type diabetes ... See more keywords
Reduced rates of overall hypoglycaemia in patients with Type 1 diabetes after switching to insulin degludec : A European, multinational, multicentre, prospective, observational study (ReFLeCT)
Sign Up to like & getrecommendations! Published in 2019 at "Diabetic Medicine"
DOI: 10.1111/dme.11_13883
Abstract: Aims: To evaluate the safety and effectiveness of switching to once‐daily insulin degludec (degludec) from other basal insulins in patients with Type 1 diabetes in routine clinical practice.Methods ... read more here.
Keywords: type diabetes; reduced rates; rates overall; insulin degludec ... See more keywords
Insulin degludec overdose may lead to long‐lasting hypoglycaemia through its markedly prolonged half‐life
Sign Up to like & getrecommendations! Published in 2018 at "Diabetic Medicine"
DOI: 10.1111/dme.13557
Abstract: Overdose of insulin often causes long‐lasting severe hypoglycaemia. Insulin degludec has the longest duration of action among the available insulin products; thus, an overdose of insulin degludec can lead to long‐lasting hypoglycaemia. In the present… read more here.
Keywords: insulin; lead long; lasting hypoglycaemia; long lasting ... See more keywords
Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin‐treated adults with type 2 diabetes and risk factors for hypoglycaemia
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.1111/dom.14504
Abstract: To compare time in range (TIR) with use of insulin degludec U100 (degludec) versus insulin glargine U100 (glargine U100) in people with type 2 diabetes. read more here.
Keywords: insulin; time range; glargine u100; insulin degludec ... See more keywords
Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co‐formulation therapy twice‐daily with free combination of GLP‐1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Clinical Practice"
DOI: 10.1111/ijcp.13734
Abstract: We compared the efficacy and safety of insulin degludec/insulin aspart co‐formulation (IDegAsp) twice‐daily to a free combination of basal insulin degludec and GLP‐1 receptor agonist liraglutide (IDeg + Lira) once‐daily for patients with inadequately controlled… read more here.
Keywords: insulin; daily free; twice daily; insulin aspart ... See more keywords
Clinical research of insulin glargine U300 basal‐bolus therapy and insulin degludec/aspart co‐formulation in type 2 diabetes mellitus: A real world experience
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Clinical Practice"
DOI: 10.1111/ijcp.14377
Abstract: Insulin degludec/aspart (IDegAsp) and insulin glargine U300 (IGlarU300) have recently emerged as popular new‐generation insulin analogues. The aim of this real‐life study was to investigate the patient profiles in which IGlarU300 and IDegAsp were preferred… read more here.
Keywords: insulin; degludec aspart; insulin glargine; glargine u300 ... See more keywords